5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.
The main objective of this study is to evaluate the interest of the SHD-E approaches after a negative result of the analysis called " gene panel " tested in routine in order to identify a genetic factor of predisposition to the cancer.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
613
blood test
CHRU Jean Minjoz
Besançon, France
NOT_YET_RECRUITINGCentre Georges-François Leclerc
Dijon, France
RECRUITINGCHU de Dijon
Dijon, France
NOT_YET_RECRUITINGCHU de Reims
Reims, France
NOT_YET_RECRUITINGPolyclinique de Courlancy
Reims, France
NOT_YET_RECRUITINGCH de Troyes
Troyes, France
NOT_YET_RECRUITINGgenetic mutations
SHD-E analysis
Time frame: inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.